← Eichor
Study identifier: NCT06569147 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Condition: AL Amyloidosis  ·  Sponsor: Brigham and Women's Hospital

PhasePhase 1/Phase 2
Planned participants49
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.

This description comes directly from the study's public registry record.

Talk to the study team

Giada Bianchi  ·  6175254953  ·  GBIANCHI1@BWH.HARVARD.EDU

Always discuss trial participation with your own doctor first.

Locations (1)

Dana-Farber Cancer InstituteBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06569147